Pharmaceutical Industry Articles & Reports - Page 8

Analyst report on AI in preclinical development in 2026: market size, FDA credibility framework and animal-testing roadmap, organ-on-chip adoption, and five named case studies.

Learn how pharmaceutical companies license proprietary R&D data to train AI foundation models. Analyze deal structures, pricing terms, and key case studies.

Learn how the Pistoia Alliance is developing Agentic AI standards, communication protocols, and validation frameworks for secure pharmaceutical R&D workflows.

Analyze GSK’s $10.6B Nuvalent acquisition. Learn about zidesamtinib & neladalkib, their clinical trial data, and the ROS1/ALK NSCLC competitive landscape.

Examine the UK MHRA drug approval process, covering Marketing Authorisation, the International Recognition Procedure (IRP), and post-Brexit regulatory pathways.

Compare top eCOA platforms for 2026, including Signant, Clario, Medidata, YPrime, and Castor. Learn about ePRO features, integration, pricing, and selection.

Analyze how agentic AI is integrated into pharma R&D through the Sanofi-Owkin partnership, and examine the build-vs-partner drug development framework.

Analyze AI adoption in pharma and biotech. Learn about 2026 industry benchmarks, drug discovery investment trends, and R&D implementation statistics.

Learn how generative antibody design models like Chai-3 operate, and analyze Pfizer's licensing strategy and the pharma AI build-versus-partner decision.

Learn how Alnylam and Inceptive use generative AI foundation models for siRNA design, exploring the $2B deal structure and pharma's build-vs-partner strategy.

Learn how closed-loop generative protein engineering accelerates CNS antibody design, and evaluate the build-vs-partner R&D playbook for pharmaceutical firms.

Analyze Annual Product Quality Review (APQR) requirements comparing FDA 21 CFR 211.180(e) and EU GMP Chapter 1. Explore data trending and automation tools.

Review the FDA approval of Datroway (datopotamab deruxtecan) for first-line metastatic TNBC. Analyze TROPION-Breast02 efficacy, survival, and safety data.

Examine the architecture and adoption of Salesforce Agentforce Life Sciences. Learn how agentic CRM, headless design, and AI impact pharma commercial teams.

Analyze Sanofi's Concierge for Field, an agentic AI tool built on Snowflake Cortex and Elementum AI to automate pharma sales prep and update operating models.

Examine ASCO 2026 HARMONi-6 trial data for ivonescimab in 1L squamous NSCLC. Understand OS outcomes, PD-1xVEGF efficacy, and Summit Therapeutics US strategy.

This analysis explains the May 2026 FDA draft guidance on nonclinical safety studies for oncology biologics, single-species toxicology, and WoE approaches.

Analyze the HelioLiver AI blood test for early liver cancer detection. Examine its clinical efficacy, CRO commercialization, and MCED adoption strategies.

Analyze Bristol Myers Squibb's deployment of Anthropic Claude to 30,000 employees. Examine agentic AI enterprise strategies and pharma change management.

Analyze the integration of agentic AI systems in pharmaceutical R&D, examining Incyte's adoption of the Kosmos AI Scientist for automated drug discovery.

Examine the $10.5B Pfizer-Innovent collaboration. This analysis covers their 12-drug ADC oncology portfolio and the China cross-border licensing playbook.

Analyze the May 2026 FDA approval of Afrezza inhaled insulin for pediatric diabetes. Review INHALE-1 clinical trial data, T1D/T2D options, and market impacts.

Review the May 2026 FDA approval of Decnupaz (pivekimab sunirine), the first CD123-targeted ADC for BPDCN. Explores clinical efficacy and launch strategies.

Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.